Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis

Inflammatory Bowel Diseases

Volumn 8, Issue 5, 2002, Pages 330-339

  Saubermann, Lawrence J ^a,e   Nakajima, Atsushi ^b   Wada, Koichiro ^a,c   Zhao, Shuping ^a   Terauchi, Yasuo ^d   Kadowaki, Takashi ^d   Aburatani, Hiroyuki ^d   Matsuhashi, Nobuyuki ^d   Nagai, Ryozo ^d   Blumberg, Richard S ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e BOSTON MEDICAL CENTER   (United States)

Author keywords

Cytokine; Inflammation; Mucosa; T lymphocyte; Transcription factor

Indexed keywords

CYTOKINE; DEXTRAN SULFATE; DRUG VEHICLE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LIGAND; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; DRUG SPECIFICITY; HETEROZYGOTE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; IMMUNOSTIMULATION; LIGAND BINDING; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; TH1 CELL; TH2 CELL; WILD TYPE;

EID: 0036743165     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200209000-00004     Document Type: Article

References (63)

1. Barnes PJ, Karin M. Nuclear factor kappa-B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-71.
2. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 1998;42:477-84.
3. Sands BE. Novel therapies for inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:323-51.
4. Neurath MF. Pathogenesis of inflammatory bowel disease: transcription factors in the spotlight. Gut 1998;42:458-9.
5. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
6. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
7. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
8. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR-gamma gene. J Biol Chem 1997;272:18779-89.
9. Delerive P, Fruchart JC, Staels B. Eurosterone meeting. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169:453-9.
10. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000; 49:497-505.
11. Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci 1999;55:932-43.
12. Andersen O, Eijsink VG, Thomassen M. Multiple variants of the peroxisome proliferator-activated receptor (PPAR) gamma are expressed in the liver of atlantic salmon (Salmo salar). Gene 2000; 255:411-18.
13. Sundvold H, Brzozowska A, Lien S. Characterisation of bovine peroxisome proliferator-activated receptors gamma 1 and gamma 2: genetic mapping and differential expression of the two isoforms. Biochem Biophys Res Commun 1997;239:857-61.
14. Mansen A, Guardiola-Diaz H, Rafter J, et al. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-51.
15. Lefebvre M, Paulweber B, Fajas L, et al. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 1999;162:331-40.
16. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor-alpha, -beta, and -gamma during rat embryonic development. Endocrinology 1998;139:2748-54.
17. Huin C, Corriveau L, Bianchi A, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J Histochem Cytochem 2000;48: 603-11.
18. Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 2000;20: 8008-17.
19. Shao G, Heyman RA, Schulman IG. Three amino acids specify coactivator choice by retinoid X receptors. Mol Endocrinol 2000; 14:1198-209.
20. Lee SK, Lee B, Lee JW. Mutations in retinoid X receptor that impair heterodimerization with specific nuclear hormone receptor. J Biol Chem 2000;275:33522-6.
21. Wang P, Anderson PO, Chen S, et al. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 2001;1:803-12.
22. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappa-B and AP-1. J Biol Chem 1999;274: 32048-54.
23. Guyton K, Bond R, Reilly C, et al. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macropbage activation. J Leukoc Biol 2001;69:631-8.
24. Heneka MT, Klockgether T, Feinstein DL. Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 2000;20:6862-7.
25. Liang YC, Tsai SH, Tsai DC, et al. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett 2001;496:12-18.
26. Uchimura K, Nakamuta M, Enjoji M, et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology 2001;33:91-9.
27. Petrova TV, Akama KT, Van Eldik LJ. Cyclopentenone prostaglandins suppress activation of microglia: downregulation of inducible nitric-oxide synthase by 15-deoxy-Delta 12, 14-prostaglandin J2. Proc Natl Acad Sci U S A 1999;96:4668-73.
28. Fahmi H, Di Battista JA, Pelletier JP, et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 2001;44:595-607.
29. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
30. Nakajima A, Wada K, Miki H, et al. Endogenous PPAR-gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001;120:460-9.
31. Kintscher U, Goetze S, Wakino S, et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2001;401:259-70.
32. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503-8.
33. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000;21:479-83.
34. Faveeuw C, Fougeray S, Angeli V, et al. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000;486:261-6.
35. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-71.
36. Yang XY, Wang LH, Chen T, et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 2000;275:4541-4.
37. Harris SG, Phipps RP. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol 2001;31:1098-105.
38. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated rReceptor gamma (PPAR-gamma) heterodimer. A basis for new therapeutic strategies. J Exp Med 2001;193:827-38.
39. Saubermann LJ, Beck P, De Jong YP, et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119:119-28.
40. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
41. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-91.
42. Egger B, Bajaj-Elliott M, MacDonald TT, et al. Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 2000;62:240-8.
43. Kitajima S, Takuma S, Morimoto M. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. J Vet Med Sci 1999;61:67-70.
44. Yoshida Y, Iwai A, Itoh K, et al. Role of inducible nitric oxide synthase in dextran sulphate sodium-induced colitis. Aliment Pharmacol Ther 2000;14(Suppl.1):26-32.
45. Shintani N, Nakajima T, Sugiura M, et al. Proliferative effect of dextran sulfate sodium (DSS)-pulsed macrophages on T cells from mice with DSS-induced colitis and inhibition of effect by IgG. Scand J Immunol 1997;46:581-6.
46. Shintani N, Nakajima T, Okamoto T, et al. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen Pharmacol 1998;31:477-81.
47. Azuma Y, Shinohara M, Wang PL, et al. 15-Deoxy-delta(12,14)-prostaglandin j(2) inhibits IL-10 and IL-12 production by macrophages. Biochem Biophys Res Commun 2001;283:344-6.
48. Hans W, Scholmerich J, Gross V, et al. Interleukin-12 induced interferon-gamma increases inflammation in acute dextran sulfate sodium induced colitis in mice. Eur Cytokine Netw 2000;11:67-74.
49. Dieleman LA, Ridwan BU, Tennyson GS, et al. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107:1643-52.
50. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549
51. Murthy S, Cooper HS, Yoshitake H, et al. Combination therapy of pentoxifylline and TNF-alpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999;13: 251-60.
52. Kojouharoff G, Hans W, Obermeier F, et al. Neutralization of tumor necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol 1997;107:353-8.
53. Neurath MF, Finotto S, Fuss I, et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001;22:21-6.
54. Marth T, Zeitz M, Ludviksson BR, et al. Extinction of IL-12 signaling promotes Fas-mediated apoptosis of antigen-specific T cells. J Immunol 1999;162:7233-40.
55. Fuss IJ, Marth T, Neurath MF, et al. Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078-88.
56. Bendixen AC, Shevde NK, Dienger KM, et al. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci U S A 2001;98:2443-8.
57. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 2000;54:275-80.
58. Wang AC, Dai X, Luu B, et al. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001;24:688-93.
59. Kitamura Y, Taniguchi T, Kimura H, et al. Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures. J Neuroimmunol 2000;106:95-104.
60. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-82.
61. Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278: 704-11.
62. Memon RA, Tecott LH, Nonogaki K, et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000;141:4021-31.
63. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000;49:539-47.